Research Topics
Species | B P RubinSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberansBrian P Rubin
Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
J Clin Oncol 20:3586-91. 2002..We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate...- A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641EBrian P Rubin
Department of Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
Cancer Res 65:6631-9. 2005.... - Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumorsBrian P Rubin
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
Lab Invest 86:981-6. 2006..This paper focuses on what is known about mechanisms of resistance in the treatment of solid tumors by small molecule kinase inhibitors... - Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumorsBrian P Rubin
Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
Arch Pathol Lab Med 130:1616-29. 2006 - Gastrointestinal stromal tumours: an updateB P Rubin
Department of Anatomic Pathology, University of Washington Medical Center, 1959 NE Pacific Street, Box 356100, Seattle, WA 98195, USA
Histopathology 48:83-96. 2006..It is the purpose of this review to summarize recent developments in GIST classification and the molecular pathogenesis of GIST... - Isochromosome 7q in adult Wilms' tumors: diagnostic and pathogenetic implicationsB P Rubin
Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Surg Pathol 24:1663-9. 2000..These genetic features may be helpful in distinguishing adult Wilms' tumors from other primary renal tumors... - Recent progress in the classification of soft tissue tumors: role of genetics and clinical implicationsB P Rubin
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
Curr Opin Oncol 13:256-60. 2001..These examples illustrate the type of progress that is being made in the classification of soft tissue tumors... - KIT mutations in GISTJonathan A Fletcher
Brigham and Women s Hospital, 75 Francis Street, Thorn 5, Boston, MA 02115, USA
Curr Opin Genet Dev 17:3-7. 2007..Alternately, the mutant kinase proteins can be targeted using HSP90 inhibitors, which result in degradation of activated KIT and/or PDGFRA, or using KIT transcriptional repressors, such as flavopiridol... - An unusual case of Erdheim-Chester disease with features of Langerhans cell histiocytosisPaul S Furmanczyk
Department of Pathology, University of Washington Medical Center, 1959 NE Pacific, P O Box 356100, Seattle, WA 98195 6100, USA
Skeletal Radiol 36:885-9. 2007..The clinical/radiologic and pathologic features that distinguish ECD and LCH as distinct entities are reviewed, and the underlying biological connection between them is discussed... - Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfallMaggie M Lam
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
Int J Gynecol Pathol 25:288-92. 2006..Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum... - Tissue response and Msx1 expression after human fetal digit tip amputation in vitroChristopher H Allan
Department of Orthopaedics and Sports Medicine, University of Washington School of Medicine Harborview Medical Center, Seattle, Washington 98104, USA
Wound Repair Regen 14:398-404. 2006..This process appears spatially associated with Msx1 expression. Msx1 expression appears increased at the regrowing tip of 57-day digits by 4 days after amputation... - Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcomaT J Wieczorek
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
Cancer 93:276-87. 2001.... - Diagnosis of gastrointestinal stromal tumors: A consensus approachChristopher D M Fletcher
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston MA 02115, USA
Hum Pathol 33:459-65. 2002.... - Diagnosis of gastrointestinal stromal tumors: a consensus approachChristopher D M Fletcher
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston MA 02115, USA
Int J Surg Pathol 10:81-9. 2002.... - Gastrointestinal stromal tumourBrian P Rubin
Department of Anatomic Pathology, Taussig Cancer Center and the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Lancet 369:1731-41. 2007..The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours... - The genetics of lipomatous tumorsB P Rubin
Department of Pathology, University of Washington Medical Center, Seattle, USA
Semin Diagn Pathol 18:286-93. 2001..The review describes characteristic cytogenetic and molecular genetic profiles and discusses their significance. The clinicopathologic features of these tumors, which are described elsewhere, will not be included in this review... 
Response to chemotherapy and predictors of survival in adult rhabdomyosarcomaN F Esnaola
Division of Surgical Oncology, Department of Surgery, Radiation Oncology and Pathology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Surg 234:215-23. 2001..Future systemic therapies should be targeted to patients with localized/locoregional disease and partial responders to conventional chemotherapy...- Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profilingA H Beck
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Oncogene 29:845-54. 2010..04). In this analysis that combined gene expression profiling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers... - Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancerB P Rubin
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Eur J Cancer Prev 10:77-82. 2001.... - KIT activation is a ubiquitous feature of gastrointestinal stromal tumorsB P Rubin
Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Cancer Res 61:8118-21. 2001..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs... - The gene expression profile of extraskeletal myxoid chondrosarcomaSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
J Pathol 206:433-44. 2005..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC... - Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 casesAmitabh Srivastava
Department of Pathology, Tufts-New England Medical Center, Boston, MA 02114, USA
Int J Surg Pathol 13:43-50. 2005..This study shows that keratin-positive EWS/PNETs have evidence of epithelial differentiation ultrastructurally, and may possibly represent a more aggressive subset of the EWS/PNET group of tumors... - Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognosticationMikelle D Bassett
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington 98195, USA
Cancer 103:409-16. 2005..This combined approach is advocated to better stratify patients for treatment purposes and follow-up... 
Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angiomaAude Rimella Le Huu
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Am J Surg Pathol 34:1563-73. 2010..Overall, our results show, for the first time, that Prox1 is an immunohistochemical biomarker helpful in confirming the diagnosis of KHE/TA and in distinguishing it from infantile hemangioma and pyogenic granuloma...- Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapyScott M Schuetze
Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA
Cancer 103:339-48. 2005..Serial FDG-PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas... - Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberansRobert B West
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Am J Surg Pathol 28:1063-9. 2004..stanford.edu/tma_portal/apod/). We conclude that Apo D is strongly expressed in DFSPs and neural lesions and may be useful in differentiating DFSP from fibrous histiocytoma... - Epithelioid sarcoma: the University of Washington experiencePatrick S Wolf
University of Washington Medical Center, Seattle, WA 98195, USA
Am J Surg 196:407-12. 2008..Epithelioid sarcoma is a rare sarcoma with a high local recurrence rate that frequently metastasizes to lymph nodes. We reviewed our experience with adjuvant therapy in patients with this disease... - TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumorsB Lawrence
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
Am J Pathol 157:377-84. 2000..Notably, a TPM3-ALK oncogene was reported recently in anaplastic lymphoma, and TPM3-ALK is thereby the first known fusion oncogene that transforms, in vivo, both mesenchymal and lymphoid human cell lineages... - Human cancers express a mutator phenotypeJason H Bielas
Department of Pathology, University of Washington, Seattle, WA 98195, USA
Proc Natl Acad Sci U S A 103:18238-42. 2006.... - Sox10: a pan-schwannian and melanocytic markerDaisuke Nonaka
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
Am J Surg Pathol 32:1291-8. 2008..Our results indicate that Sox10 will serve as a more sensitive and specific marker for the diagnosis of melanocytic and schwannian tumors than S100 protein... - Pathology of soft tissue sarcomaBrian P Rubin
Department of Anatomic Pathology, Lerner Research Institute and Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Natl Compr Canc Netw 5:411-8. 2007.... - Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumorsDaisuke Nonaka
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
J Cutan Pathol 35:1014-9. 2008..S100 family of proteins consists of over 20 members. We report on S100 subtypes in malignant melanomas (MMs), and BPNSTs and MPNSTs to investigate differential expression... - A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 103:690-5. 2006.... - Absence of BRAF and NRAS mutations in uveal melanomaFrank Cruz
Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Cancer Res 63:5761-6. 2003..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway... - FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcomaCheryl B Vernon
Department of Radiology (Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
Skeletal Radiol 32:139-42. 2003..Evaluating the heterogeneity of the tumor at baseline and after response to therapy can provide insight into prognosis and treatment planning... - Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumorsSamuel Singer
Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
J Clin Oncol 20:3898-905. 2002..The aim of this study was to evaluate the prognostic relevance for KIT mutations in a series of GISTs in which the mutations were evaluated intensively by genomic and cDNA sequencing... - Neonate with a fibrosarcoma and consumptive coagulopathyMaryam Asgari
Division of Dermatology, Department of Pediatrics, University of Washington, 4800 Sand Point Way NE, Seattle, WA 98105, USA
J Am Acad Dermatol 50:S23-5. 2004..We discuss subtle differences in clinical presentations that might aid in differentiating vascular tumors from fibrosarcomas... - The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusRobert B West
Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Am J Pathol 165:107-13. 2004..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase... - Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Oncogene 23:7780-90. 2004..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated... - Determination of stromal signatures in breast carcinomaRobert B West
Department of Pathology, Stanford University Medical Center, Stanford, California, USA
PLoS Biol 3:e187. 2005..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells... - KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?Jonathan A Fletcher
Am J Pathol 161:737-8; author reply 738-9. 2002 - Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasmsJoshua Weaver
Pathology and Laboratory Medicine Institute, Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA
Mod Pathol 21:943-9. 2008.... - Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterationsMichael C Heinrich
Department of Medicine, Division of Hematology/Oncology, Oregon Health Sciences University and Portland VA Medical Center, USA
Hum Pathol 33:484-95. 2002..These cytogenetic aberrations are undoubtedly important in GIST pathogenesis, but currently they do not play a key role as diagnostic adjuncts... - Pleomorphic angiomatoid fibrous histiocytoma: a case confirmed by fluorescence in situ hybridization analysis for EWSR1 rearrangementIlan Weinreb
Department of Pathology and Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada
J Cutan Pathol 35:855-60. 2008..Pleomorphic AFH should be included in the differential diagnosis of atypical mesenchymal tumors of skin and superficial subcutis and molecular testing may prove helpful in this regard... - Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed casesAndrew L Folpe
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
Am J Surg Pathol 29:1025-33. 2005.... - Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberansSabine C Linn
Departments of Pathology, Genetics, and Biochemistry, and Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, California 94305, USA
Am J Pathol 163:2383-95. 2003.... - Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literatureAndrew L Folpe
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
Am J Surg Pathol 28:1-30. 2004..Recognition of PMTMCT is critical, as complete resection cures intractable OO. Immunohistochemistry and RT-PCR for FGF-23 confirm the role of this protein in PMTMCT-associated OO... - TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studiesJefferson Terry
Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
Am J Surg Pathol 31:240-6. 2007..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer... - Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesionsBrian P Rubin
Departments of Anatomic Pathology and Molecular Genetics, Taussig Cancer Center and Lerner Research Institute, The Cleveland Clinic L25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Skeletal Radiol 36:267-8. 2007 - Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcomaDavid M Thomas
Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, and Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Center, Victoria, Melbourne, Australia
J Cell Biol 167:925-34. 2004..Physiologic coupling of osteoblast differentiation to cell cycle withdrawal is mediated through runx2 and p27KIP1, and these processes are disrupted in osteosarcoma... - Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiationAudrey N Schuetz
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
Mod Pathol 18:1403-10. 2005..Desmosomal and adherens junction protein expression was rare to absent. Our findings provide additional evidence that ES/PNET frequently show partial epithelial differentiation... - Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1Douglas R Stewart
J Med Genet 44:e61. 2007..We hypothesise that the LOH of NF1 and lack of KIT and PDGFRA mutations are evidence of an alternative pathogenesis in NF1-associated GISTs...